Neumora's competitive advantage lies in its multi-program pipeline targeting innovative mechanisms of action including kappa opioid receptor antagonism, vasopressin 1a receptor antagonism, and M4 positive allosteric modulation. Multiple clinical data readouts expected in 2026, including KOASTAL-2 and KOASTAL-3 trials, present significant value creation opportunities if successful.
Cyborg Score Rationale
Clinical-stage biotech with differentiated pipeline and promising early data (NMRA-511 showed clinically meaningful effect in Alzheimer's agitation; NMRA-215 showed class-leading weight loss). Near-term catalysts are strong but execution risk is inherent to pre-commercial stage. Recent analyst upgrade to Outperform (RBC Capital) supports thesis.
Top Insights
NMRA-511 demonstrated clinically meaningful 15.7-point reduction in Alzheimer's disease agitation (CMAI total score), outperforming pre-specified comparators
NMRA-215 obesity program shows class-leading results: 19% weight loss monotherapy, up to 26% in combination with semaglutide
Multiple clinical readouts scheduled for 2026 (KOASTAL-2/-3 expected Q2 2026) provide key near-term value catalysts
RBC Capital Markets upgraded stock from Sector Perform to Outperform with $4 to $7 price target
Named Competitors
Donanemab — Anti-amyloid antibody for Alzheimer's disease
Lecanemab — Anti-amyloid monoclonal antibody for early Alzheimer's
GLP-1 agonists — Obesity and weight loss treatments
Recent Developments
(November 2025) Portfolio updates including positive preclinical NLRP3 inhibitor data for NMRA-215 obesity program
(October 2025) Announced class-leading obesity results and plans to initiate Phase 1 study with NMRA-215
(Late 2025) NMRA-511 topline data reported for Alzheimer's disease agitation with positive Phase 1b results
Open the full interactive Neumora Therapeutics, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.